Lilly and AstraZeneca Open Patient Enrolment for Alzheimer’s Treatment

Lilly and AstraZeneca Open Patient Enrolment for Alzheimer’s Treatment
Eli Lilly and Company and AstraZeneca, who previously partnered to study an investigational treatment for Alzheimer’s disease, have announced the enrollment of the first patient in the study, called AMARANTH. The Phase II/III study aims to evaluate the safety and efficacy of oral beta secretase cleaving enzyme (BACE) inhibitor, AZD3293. The drug currently in study, known either

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *